| Literature DB >> 35722649 |
Rijo M Choorakuttil1, Bavaharan Rajalingam2, Shilpa R Satarkar3, Lalit K Sharma4, Anjali Gupta5, Akanksha Baghel6, Neelam Jain7, Devarajan Palanisamy8, Ramesh Shenoy9, Karthik Senthilvel10, Sandhya Dhankar11, Kavita Aneja12, Somya Dwivedi13, Shweta Nagar14, Sonali Kimmatkar Soni15, Gulab Chhajer16, Sunitha Pradeep17, Prashant M Onkar18, Avni K P Skandhan19, Eesha Rajput20, Renu Sharma21, Srinivas Shentar22, Suresh Saboo23, Amel Antony24, M R Balachandran Nair25, Tejashree Y Patekar26, Bhupendra Ahuja27, Hemant Patel28, Mohanan Kunnumal29, Rajendra K Sodani30, M V Kameswar Rao31, Pushparaj Bhatele32, Sandeep Kavthale33, Deepak Patkar34, Rajeev Singh35, Amarnath Chelladurai36, Praveen K Nirmalan37.
Abstract
Aim The aim of the study is to determine improvements in perinatal mortality at the end of the first 2 years from the initiation of the Samrakshan program of the Indian Radiological and Imaging Association. Methods Samrakshan is a screening program of pregnant women that uses trimester-specific risk assessment protocols including maternal demographics, mean arterial pressure, and fetal Doppler studies to classify women as high risk or low risk for preterm preeclampsia (PE) and fetal growth restriction (FGR). Low dose aspirin 150 mg daily once at bedtime was started for pregnant women identified as high risk in the 11-13 6/7 weeks screening. The third-trimester screening focused on the staging of FGR and protocol-based management for childbirth and risk assessment for PE. Outcomes of childbirth including gestational age at delivery, development of PE, and perinatal mortality outcomes were collected. Results Radiologists from 38 districts of 16 states of India participated in the Samrakshan program that screened 2,816 first trimester, 3,267 second trimester, and 3,272 third trimester pregnant women, respectively. At 2 years, preterm PE was identified in 2.76%, preterm births in 19.28%, abnormal Doppler study in 25.76% of third trimester pregnancies, and 75.32% of stage 1 FGR delivered at term. The neonatal mortality rate was 9.86/1,000 live births, perinatal mortality rate was 18.97/1,000 childbirths, and maternal mortality was 58/100,000 live births compared with 29.5, 36, and 113, respectively in 2016. Conclusion Fetal Doppler integrated antenatal ultrasound studies in Samrakshan led to a significant reduction in preterm PE rates, preterm birth rates, and a significant improvement in mean birth weights. Perinatal, neonatal, and maternal mortality rates are significantly better than the targets for 2030 set by the Sustainable Development Goals-3. Indian Radiological Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: fetal Doppler; fetal growth restriction; neonatal mortality; perinatal mortality; preeclampsia
Year: 2022 PMID: 35722649 PMCID: PMC9200467 DOI: 10.1055/s-0041-1741087
Source DB: PubMed Journal: Indian J Radiol Imaging ISSN: 0970-2016
Educational programs as part of the Samrakshan Program
| States/Union Territory covered through state specific CMEs | Chandigarh, Chhattisgarh, Gujarat, Haryana, Kerala, Madhya Pradesh, Maharashtra, Odisha, Puducherry, Punjab, Rajasthan, Tamil Nadu, Uttar Pradesh |
| Number of Fetal Radiology Webinars conducted | 30 (700–900 participants in each webinar) |
| Outreach programs | Guna, Harda, Sagar—Madhya Pradesh |
| Multilingual Health Education articles | 24 (English, Hindi, Malayalam, Tamil, Kannada, Telugu, Marathi, Gujarati, Odia) |
| Educational Videos | 11 |
| Original Research Articles | 11 |
| Protocols, Editorials, and Interviews | 6 |
Clinical and demographic details of the 2,816 first trimester pregnant women screened through Samrakshan
| Characteristic | |
|---|---|
| Nulliparous | 1,632 (57.95%) |
| Spontaneous conception | 2,716 (96.45%) |
| Mean age ± SD | 27.45 ± 4.74 |
| Maternal Age >35 y | 231 (8.20%) |
| Body mass index <18.5 kg/m 2 | 204 (7.24%) |
| Body mass index 25–29.9 kg/m 2 | 788 (27.99%) |
| Body mass index ≥30 kg/m 2 | 328 (11.65%) |
| Chronic hypertension | 30 (1.07%) |
| Diabetes mellitus | 17 (0.60%) |
| Pregnant woman mother had preeclampsia | 26 (0.92%) |
| Preeclampsia in previous childbirth | 111 (9.38%) |
Clinical details of the 3,272 third trimester pregnant women screened in Samrakshan
| Characteristic | |
|---|---|
| Pregnant woman developed preeclampsia | 108 (3.30%, 95% CI: 2.74, 3.97) |
| Preterm preeclampsia | 97 (89.81%) of 108 |
| Abnormal Doppler study | 843 (25.76%, 95% CI: 24.29, 27.29) |
| Mean uterine artery PI >95 th percentile | 421 (12.87%, 95% CI: 11.76, 14.06) |
| Umbilical artery PI >95 th percentile | 198 (6.05%, 95% CI: 5.28, 6.92) |
| Middle cerebral artery PI <5 th percentile | 305 (9.32%, 95% CI: 8.37, 10.37) |
| Cerebro-placental ratio <5 th percentile | 443 (13.54%, 95% CI: 12.41, 14.75) |
| No FGR | 2,616 (71.95%, 95% CI: 78.54, 81.29) |
| Stage 1 FGR | 362 (11.06%, 95% CI: 10.03, 12.18) |
| Stage 2 FGR | 5 (0.15%, 95% CI: 0.06, 0.36) |
| Stage 3 FGR | 14 (0.43%, 95% CI: 0.26, 0.72) |
| Stage 4 FGR | 5 (0.15%, 95% CI: 0.06, 0.36) |
| Small for gestational age | 270 (8.25%, 95% CI: 7.36, 9.24) |
| Estimated fetal weight (EFW)< 3 rd percentile | 225 (6.88%, 95% CI: 6.06, 7.80) |
| EFW 3 rd to 10 th percentile | 434 (13.26%, 95% CI: 12.14, 14.47) |
| EFW 10 th to 50 th percentile | 1,768 (54.03%, 95% CI: 52.32, 55.75) |
| EFW >50 th percentile | 845 (25.83%, 95% CI: 24.35, 27.35) |
Abbreviations: CI, confidence interval; EFW, estimated fetal weight; FGR, fetal growth restriction.
Childbirth outcomes of 1,740 pregnant women screened in the 3 rd trimester of Samrakshan
| Characteristic | |
|---|---|
| Gestational age at delivery <34 wk | 43, 2.48% (95% CI: 1.84, 3.31) |
| Gestational age at delivery 34 to <37 wk | 292, 16.78% (95% CI: 15.1, 18.61) |
| Overall preterm births (<37 wk) | 335, 19.28% (95% CI: 17.47, 21.17) |
| Mother developed preeclampsia | 62, 3.56% (95% CI: 2.79, 4.54) |
| Preeclampsia <37 wk | 48 (77.41%) of 62 |
| Birthweight <2,500 g | 357, 20.51% (95% CI: 18.69, 22.48) |
| Stillborn | 16 (0.92%) |
| Neonatal deaths | 17 (0.99%) |
| Neonatal mortality rate | 9.86 per 1,000 live births |
| Perinatal mortality rate | 18.97 per 1,000 childbirths |
| Maternal mortality rate | 58.00 per 100,000 live births |
Comparison of the July 2020 Samrakshan data with the August 2021 data
| Characteristics | Data up to July 31, 2020 | Data up to August 1, 2021 | |
|---|---|---|---|
| Stage 1 FGR | 27.27% | 11.06% | <0.0001 |
| Stage 2 FGR | 0.38% | 0.15% | 0.41 |
| Stage 3 FGR | 5.30% | 0.43% | <0.0001 |
| Stage 4 FGR | 0.76% | 0.15% | 0.05 |
| Small for gestational age | 4.92% | 8.25% | 0.06 |
| Stage 1 FGR delivered at term | 56.94% | 75.32% | <0.001 |
| Preterm births | 29.54% | 19.28% | 0.0001 |
| Mean birthweight ± SD (g) | 2636.99 ± 568.95 | 2747.89 ± 515.39 | 0.001 |
| Maternal preterm PE | 9.85% | 2.76% | <0.0001 |
| Neonatal mortality rate | 15.32 | 9.86 | 0.007 |
| Perinatal mortality rate | 26.52 | 18.97 | 0.004 |
Abbreviations: EFW, estimated fetal weight; FGR, fetal growth restriction.